Furthermore, the utilization of the clinically approved Src inhibitor Dasatinib can counteract the suppressive paracrine effect of PCs on the sensitivity of third‐generation TKIs in EGFR‐mutated cancer cells. The gene discussed is EGFR; the disease is cancer.